Navigation Links
OHSU AIDS vaccine candidate appears to completely clear virus from the body
Date:9/11/2013

PORTLAND, Ore. An HIV/AIDS vaccine candidate developed by researchers at Oregon Health & Science University appears to have the ability to completely clear an AIDS-causing virus from the body. The promising vaccine candidate is being developed at OHSU's Vaccine and Gene Therapy Institute. It is being tested through the use of a non-human primate form of HIV, called simian immunodeficiency virus, or SIV, which causes AIDS in monkeys. Following further development, it is hoped an HIV-form of the vaccine candidate can soon be tested in humans. These research results were published online today by the journal Nature. The results will also appear in a future print version of the publication.

"To date, HIV infection has only been cured in a very small number of highly-publicized but unusual clinical cases in which HIV-infected individuals were treated with anti-viral medicines very early after the onset of infection or received a stem cell transplant to combat cancer," said Louis Picker, M.D., associate director of the OHSU Vaccine and Gene Therapy Institute. "This latest research suggests that certain immune responses elicited by a new vaccine may also have the ability to completely remove HIV from the body."

The Picker lab's approach involves the use of cytomegalovirus, or CMV, a common virus already carried by a large percentage of the population. In short, the researchers discovered that pairing CMV with SIV had a unique effect. They found that a modified version of CMV engineered to express SIV proteins generates and indefinitely maintains so-called "effector memory" T-cells that are capable of searching out and destroying SIV-infected cells.

T-cells are a key component of the body's immune system, which fights off disease, but T-cells elicited by conventional vaccines of SIV itself are not able to eliminate the virus. The SIV-specific T-cells elicited by the modified CMV were different. About 50 percent of monkeys given highly pathogenic SIV after being vaccinated with this vaccine became infected with SIV but over time eliminated all trace of SIV from the body. In effect, the hunters of the body were provided with a much better targeting system and better weapons to help them find and destroy an elusive enemy.

"Through this method we were able to teach the monkey's body to better 'prepare its defenses' to combat the disease," explained Picker. "Our vaccine mobilized a T-cell response that was able to overtake the SIV invaders in 50 percent of the cases treated. Moreover, in those cases with a positive response, our testing suggests SIV was banished from the host. We are hopeful that pairing our modified CMV vector with HIV will lead to a similar result in humans."

The Picker lab is now investigating the possible reasons why only a subset of the animals treated had a positive response in hopes that the effectiveness of the vaccine candidate can be further boosted.


'/>"/>

Contact: Todd Murphy
murphyt@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Walgreens to Help Provide Up to 3 Million Life-Saving Vaccines for Children who Need Them Most Through Donation to United Nations Foundation’s Shot@Life Campaign
2. Pain-free microneedle influenza vaccine is effective, long-lasting
3. African-American women less likely to receive HPV vaccine than whites, Pitt study finds
4. China Human Vaccine Industry Outlook 2012-2015: Worldwide Industry Latest Market Share, Strategy, Growth, Size, Trends And Forecast Research Report
5. Global Vaccine Market Trends and Disease Indications Analysis with 2022 Forecasts in New Research Report at RnRMarketResearch.com
6. Investigational malaria vaccine found safe and protective
7. Global and China Human Vaccine Market Analysis & 2017 Forecasts in New Research Report at RnRMarketResearch.com
8. Chinese CDC and Aeras sign agreement to collaborate on TB vaccine R&D
9. China Animal Vaccine Market Worth 15.9 Billion By 2016 in New Research Report at RnRMarketResearch.com
10. Building Vaccine Accountability in Wisconsin Immunization Registry (WIR©™) Systems with VTrckS
11. China Poultry Vaccine Industry Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... A global center of excellence ... The state of the art center will provide advanced surgical care (heart surgery), ... providing heart patients longer lives. , North American Veterinary Heart Center, the “Heart ...
(Date:7/26/2017)... ... July 26, 2017 , ... The Amnesty Rally 2017 will be ... Park at 3313 Bernstein Park Drive in Monroe (adjacent to the Louisiana Purchase Gardens ... help reduce gun violence throughout Monroe. Citizens can turn in unregistered, illegally-held and imitation ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or older ... to improve asthma control in the population are not well described. In a study ... an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... the sales department joining as Regional Account Manager for the Northeast and Florida ... in the liquidation of their obsolete medical assets. , Jennifer joins Centurion with ...
(Date:7/25/2017)... ... July 25, 2017 , ... Therachat ... will be exhibiting and providing demos of its smart journaling platform at the ... Center in Washington D.C. from August 3-6, 2017. , The APA Annual Convention ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
(Date:7/21/2017)... 21, 2017  Endo International plc (NASDAQ: ... review of its manufacturing network, the Company will be ... in Huntsville, Alabama . The closure ... the next 12 to 18 months. The ... volumes of commoditized products and these restructuring actions are ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
Breaking Medicine Technology: